INAB:NASDAQIN8bio, Inc. Analysis
Data as of 2026-05-22 - not real-time
$1.66
Latest Price
8/10Risk
Risk Level: High
Executive Summary
IN8bio trades at $1.66, just above its $1.40 support level, with a bullish MACD histogram and a neutral‑to‑slightly‑positive RSI of 57, suggesting limited short‑term downside. Technical indicators are complemented by an extreme‑greed sentiment reading (91.77) and a calculated upside of over 270% versus current price, indicating strong market optimism.
The company just reported a striking ~97% improvement in progression‑free survival for glioblastoma in early data, slated for presentation at ASCO 2026, which could catalyze a re‑rating. Despite having no revenue and negative cash flow, IN8bio holds $21.9 M in cash against $2.35 M of debt, providing a runway for continued R&D. The stock’s high beta (1.8) and 30‑day volatility (≈57%) underline significant price swings, while the lack of dividends and a negative earnings profile reinforce its growth‑centric profile.
The company just reported a striking ~97% improvement in progression‑free survival for glioblastoma in early data, slated for presentation at ASCO 2026, which could catalyze a re‑rating. Despite having no revenue and negative cash flow, IN8bio holds $21.9 M in cash against $2.35 M of debt, providing a runway for continued R&D. The stock’s high beta (1.8) and 30‑day volatility (≈57%) underline significant price swings, while the lack of dividends and a negative earnings profile reinforce its growth‑centric profile.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and price near support
- Positive early GBM trial data
- Substantial upside potential per analyst targets
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Upcoming ASCO 2026 presentation
- Cash runway supporting continued development
- Undervalued price relative to book and target multiples
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Pipeline of multiple γδ T‑cell candidates
- Potential for breakthrough approvals in oncology/autoimmune space
- Long‑term market upside if trials succeed
Key Metrics & Analysis
Financial Health
P/E Ratio-1.6
ROE-103.55%
ROA-52.75%
Debt/Equity10.33
P/B Ratio0.7
Op. Cash Flow$-14537000
Free Cash Flow$-7128875
Industry P/E27.6
Technical Analysis
TrendNeutral
RSI57.5
Support$1.40
Resistance$1.75
MA 20$1.56
MA 50$1.55
MA 200$1.89
MACDBullish
VolumeStable
Fear & Greed Index91.77
Valuation
Target Price$6.25
Upside/Downside277.28%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.80
Volatility57.60%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.